The global Enzyme Linked Immunosorbent Assay (ELISA) Market, by Method (Direct ELISA, Indirect ELISA, Sandwich ELISA, and Competitive ELISA), by Application (Vaccine Development, Immunology, Diagnostics, Toxicology, Drug Monitoring & Pharmaceutical Industry & Transplantation), By Technology (Chemiluminescent, Colorimetric, & Fluorescent), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 1,583.4 million in 2016 and is projected to exhibit a CAGR of 5.1% over the forecast period (2017 – 2025), as highlighted in a new report published by Coherent Market Insights. Enzyme Linked Immunosorbent Assay (ELISA) Market is expected to gain significant traction over the forecast period, owing to the launch of novel assays and increasing demand for cost efficient tools due to increasing incidence of chronic infectious diseases and cancer. For instance, According to a National Cancer Institute, 2016, an estimated 16.8 million new cases of cancer were diagnosed in the U.S., with around 595,690 deaths from the disease. The number of people suffering from cancer is expected to rise to 19 million by 2024.
Request a SAMPLE COPY of the Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1505
Technological advancements in ELISA test kits are expected to foster growth of global Enzyme Linked Immunosorbent Assay (ELISA) Market
Extensive research and development in the field of immunoassay and diagnostics is leading to increasing applications and novel approaches for incorporation of ELISA in various medical fields. This has resulted in expansion of the range of Enzyme Linked Immunosorbent Assay (ELISA) products used in clinical and medical approaches. For instance, Inova Diagnostics, in November 2016, received U.S. FDA approval for QUANTA Lite, a Calprotectin Extended range of quantitative ELISA assay that aids in the diagnosis of Inflammatory Bowel Disease (IBD) and helps to differentiate IBD from Irritable Bowel Syndrome (IBS). Moreover, a recent test is developed by Center for Infection and Immunity at University of Columbia in March 2018, extends a window for accurate detection of Zika infection, which is complex with molecular diagnostics procedures. The new ZIKV-NS2B-concat ELISA is a faster, less expensive blood test, and clinical tool for accurate detection of Zika from weeks to months after onset of infection facilitating a powerful tool for the clinicians to make quick decisions for their patients. In July 2015, Bio-Rad Laboratories, Inc. received the U.S. Food and Drug Administration pre-market approval for BioPlex 2200 HIV Ag-Ab assay, which is the company’s fifth generation HIV diagnostic test that produced efficient diagnostic test results for HIV.
Browse 42 Market Data Tables and 36 Figures spread through 170 Pages and in-depth TOC on “Enzyme Linked Immunosorbent Assay (ELISA) Market”- by Method (Direct ELISA, Indirect ELISA, Sandwich ELISA and Competitive ELISA), by Application (Vaccine Development, Immunology, Diagnostics, Toxicology, Drug Monitoring & Pharmaceutical Industry & Transplantation), By Technology (Chemiluminescent, Colorimetric, & Fluorescent), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2025
To know the latest trends and insights prevalent in Enzyme Linked Immunosorbent Assay (ELISA) Market, click the link below:
The market players are focused towards expansion of their product portfolio and geographic reach by adoption of inorganic strategies such as mergers and acquisitions to maintain their positions in the market. For instance, in March 2017, Thermo Fisher Scientific, Inc. acquired Core Informatics and added it to analytical Instruments segment to strengthen its existing informatics solutions and bio production offerings. Furthermore, the company players are also focusing on research and development for introducing novel ELISA assays and test kits in to the market to stand out and retain their positions in the market. For instance, in August 2016, ALPCO introduced new and improved, highly specific Total Adiponectin and HMW & Total Adiponectin ELISAs, this colorimetric assays provides researchers with the confidence to measure adiponectin.
Key Takeaways of Enzyme Linked Immunosorbent Assay (ELISA) Market:
- The global Enzyme Linked Immunosorbent Assay (ELISA) Market is expected to exhibit a CAGR of 5.1% over the forecast period, owing to increasing incidence of infectious diseases coupled with rising adoption of cost-effective diagnostic solutions
- Among method segment, the indirect ELISA segment dominates the global ELISA market, owing to high sensitivity and flexibility offered by the method for determination of concentration of a target substance in a sample
- Among technology, diagnostics segment held dominant position in the global ELISA market, owing to potential of the assay to detect wide variety of disease in human and screen large number of samples
- Among region, North America is expected to dominate the global Enzyme Linked Immunosorbent Assay (ELISA) Market, owing to introduction of innovative solutions in market to overcome issues faced by the clinical facilities and other users
- The key players operating in global Enzyme Linked Immunosorbent Assay (ELISA) Market include Bio-Rad Laboratories, Inc., Enzo Life Sciences, Inc., Thermo Fisher Scientific, Inc., Biomerieux S.A., Alpco, BioLegand, Inc., Zeus Scientific, Inc., and Shenzhen YHLO Biotech Co., Ltd.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Company Name: Coherent Market Insights
Contact Person: Mr. Shah
Email: Send Email
Address:1001 4th Ave, #3200
Country: United States